Historical Development of CJC-1295: From Discovery to Modern Research Peptide Applications
Historical Development of CJC-1295: From Discovery to Modern Research Peptide Applications
The story of CJC-1295 begins not with the peptide itself but with the decades-long scientific effort to understand how the body controls growth hormone secretion. That foundational work, stretching from the 1970s through the 2000s, created the conceptual and technical framework that made CJC-1295 possible.
This article traces the history of CJC-1295 from the discovery of growth hormone-releasing hormone (GHRH) through the iterative development of increasingly stable GHRH analogs, ending with where CJC-1295 stands today as a research peptide tool in endocrine and metabolic science.
Disclaimer: CJC-1295 is a research chemical intended for laboratory investigation only. It is not approved for human or veterinary use. This historical overview is for educational purposes. Palmetto Peptides provides research-grade peptides for qualified scientific use in compliance with applicable law.
The Discovery of GHRH (1982 to 1984)
For years, scientists knew that the hypothalamus controlled growth hormone release from the pituitary gland, but the specific molecular signal responsible remained unidentified until the early 1980s.
In 1982, Guillemin and colleagues isolated and characterized a 44-amino acid peptide from the pancreatic tumor tissue of a patient with acromegaly (a condition caused by excess GH secretion) that potently stimulated GH release from pituitary cells. This peptide was designated growth hormone-releasing hormone, or GHRH. Nearly simultaneously, Rivier and Vale's laboratory published the isolation of a second form of GHRH from hypothalamic tissue.
The key finding was that the first 29 amino acids of the 44-residue GHRH molecule retained full biological activity at the GHRH receptor. This truncated fragment, GHRH(1-29), became the foundation for all subsequent synthetic analog development, including sermorelin and eventually CJC-1295.
First-Generation Analogs and the Problem of Rapid Degradation (1985 to 1995)
With the structure of GHRH established, pharmaceutical researchers began synthesizing shorter, modified analogs. Sermorelin, GHRH(1-29)NH2, was the first such analog to gain regulatory attention, receiving FDA approval for pediatric GH deficiency diagnosis in 1997.
However, sermorelin and native GHRH shared a critical limitation: rapid enzymatic degradation in plasma. The primary enzyme responsible, dipeptidyl peptidase IV (DPP-IV), cleaved the Tyr-Ala bond between positions 1 and 2 of the GHRH sequence within minutes. Frohman and colleagues (1989) characterized this specific enzymatic pathway in detail, providing the mechanistic target for second-generation analog design.
Second-Generation Analogs: Achieving DPP-IV Resistance (1995 to 2005)
The key structural insight was to substitute the alanine at position 2 of the GHRH sequence with an amino acid that DPP-IV cannot recognize as a cleavage substrate. Alpha-aminoisobutyric acid (Aib), a non-natural alpha-methyl amino acid, proved to be an effective substitute. The additional methyl group creates steric hindrance that blocks DPP-IV binding without eliminating GHRHR recognition.
Combined with other stabilizing substitutions at positions susceptible to other circulating peptidases, these modifications produced GHRH analogs with dramatically extended biological half-lives. CJC-1293, a tetrasubstituted GHRH analog, represented an intermediate step in this development process.
The Drug Affinity Complex Innovation: ConjuChem and CJC-1295 (2001 to 2006)
The most significant advance in GHRH analog pharmacokinetics came from exploiting a naturally long-lived plasma protein: albumin.
ConjuChem, a Canadian biotechnology company, developed the Drug Affinity Complex (DAC) technology platform as a general strategy for extending peptide drug half-lives. The platform uses a reactive maleimide group to form a covalent bond with the free cysteine-34 thiol group on serum albumin. Applied to their DPP-IV-resistant GHRH analog, ConjuChem produced CJC-1295 with DAC.
Teichman et al. (2006) published landmark pharmacokinetic data in the Journal of Clinical Endocrinology and Metabolism demonstrating that a single administration of CJC-1295 with DAC produced measurable GH and IGF-1 elevation persisting for more than six days. This represented a roughly 10,000-fold extension of plasma half-life compared to native GHRH.
Historical Timeline
| Year | Milestone |
|---|---|
| 1982 | GHRH isolated from pancreatic tumor tissue by Guillemin and colleagues |
| 1982 to 1984 | GHRH(1-44) and GHRH(1-29) characterized; active N-terminal domain identified |
| 1989 | DPP-IV cleavage mechanism for GHRH characterized by Frohman et al. |
| 1997 | Sermorelin approved by FDA for pediatric GH deficiency diagnosis |
| Late 1990s | Tetrasubstituted DPP-IV-resistant GHRH analogs developed, including CJC-1293 |
| 2001 to 2004 | ConjuChem develops DAC technology; CJC-1295 synthesized |
| 2006 | Teichman et al. publish landmark CJC-1295 PK/PD data |
| 2006 | Alba et al. demonstrate in vivo efficacy in GHRH-knockout mouse model |
| 2006 to present | CJC-1295 establishes its place in preclinical research literature |
CJC-1295 in the Research Peptide Landscape (2006 to Present)
Following the Teichman (2006) publication, CJC-1295 rapidly attracted attention in the preclinical research community. Alba et al. (2006) published animal model data showing that once-daily CJC-1295 administration normalized growth in GHRH-knockout mice. Ionescu and Frohman (2006) showed that pulsatile GH secretion was preserved even during sustained CJC-1295 exposure, addressing concerns about tonic stimulation causing pituitary desensitization.
Over the following decade, CJC-1295 became an established research tool for studies of the GH/IGF-1 axis, metabolic effects of sustained GH elevation, and exploration of GHRH receptor biology.
The ConjuChem DAC Platform: Broader Significance
CJC-1295 was not the only compound developed using ConjuChem's Drug Affinity Complex technology. The DAC platform was designed as a general-purpose half-life extension strategy applicable to multiple peptide drugs. CJC-1295 became the most widely recognized application of the technology in the GHRH analog space because of the strong pharmacokinetic and pharmacodynamic data generated in 2006.
The broader significance of the DAC platform for peptide research is that it demonstrated a practical path to dramatically extending peptide bioavailability without requiring continuous infusion or complex drug delivery systems. For laboratory research, this translated into the ability to study sustained GHRH receptor activation in animal models with practical once-daily or less-frequent dosing schedules, removing a major logistical obstacle to longer-duration GH axis studies.
Nomenclature and the Literature: Navigating CJC-1295 References
One challenge for researchers reviewing the published literature on CJC-1295 is inconsistent nomenclature. Different publications, particularly older ones from the 2006 to 2010 era, may use slightly different names for the same or closely related compounds. A brief guide:
- CJC-1295 typically refers to the full DAC-bearing compound in foundational publications by Teichman, Ionescu, and Alba.
- Modified GRF 1-29 or Mod GRF 1-29 refers to the DPP-IV-resistant backbone without the DAC modification, which is what many researchers mean when they say "CJC-1295 without DAC."
- CJC-1293 refers to an earlier precursor analog in ConjuChem's development pipeline that preceded CJC-1295.
- GRF(1-29) or GHRH(1-29) typically refers to the unmodified native sequence fragment (equivalent to sermorelin).
When searching the literature, researchers should use multiple search terms and verify the structural description in the methods section of any paper to confirm which specific compound was used.
Research-grade CJC-1295 is available from Palmetto Peptides for qualified laboratory researchers.
Related Research
- Complete Guide to CJC-1295
- Mechanism of Action of CJC-1295
- CJC-1295 Pharmacokinetics and Half-Life
- CJC-1295 vs Sermorelin
- IGF-1 Responses in CJC-1295 Research
- CJC-1295 DAC vs No DAC
Frequently Asked Questions
Who originally developed CJC-1295? CJC-1295 was developed by ConjuChem, a Canadian biotechnology company, as part of its Drug Affinity Complex (DAC) peptide extension platform applied to a DPP-IV-resistant GHRH analog backbone.
What does the CJC designation in CJC-1295 stand for? CJC refers to ConjuChem, the company that developed the compound. The number 1295 is an internal compound identifier from ConjuChem's development pipeline.
Was CJC-1295 ever in clinical trials? Yes, early phase clinical pharmacology studies including the Teichman 2006 paper evaluated CJC-1295 in human subjects. The compound has not progressed to approved clinical use.
Is the no-DAC variant (Mod GRF 1-29) a separate historical development from CJC-1295? The no-DAC variant refers to the DPP-IV-resistant GHRH analog backbone without the albumin-binding modification. It represents the intermediate compound in the development path leading to the full DAC-bearing CJC-1295 and is often called Modified GRF 1-29 or CJC-1295 without DAC in the research literature.
Summary
CJC-1295's development traces a clear scientific arc from the 1982 discovery of GHRH, through characterization of its rapid enzymatic degradation, to the engineering of DPP-IV-resistant analogs and ultimately the albumin-binding DAC modification. This history reflects iterative progress in applied peptide pharmacology and established CJC-1295 as a uniquely useful research tool for studying the growth hormone axis in animal and cell-based models.
References
- Guillemin R, et al. "Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly." Science. 1982;218(4572):585-587.
- Rivier J, et al. "Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour." Nature. 1982;300(5889):276-278.
- Frohman LA, Downs TR, Heimer EP, Felix AM. "Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma." Journal of Clinical Investigation. 1989;83(5):1533-1540.
- Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295." Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- Alba M, et al. "Once-daily administration of CJC-1295 normalizes growth in the GHRH knockout mouse." American Journal of Physiology. 2006;291(6):E1290-E1294.
Author: Palmetto Peptides Research Team | Last Updated: June 2025